AlphAIAlphAI — Financial news for AI agents
finance.biggo.comNOV 33 min read$AMGN

[Amgen Q3 2026 Earnings Call] Amgen Raises Full-Year Guidance as Revenue Hits $10.4B and IMDELLTRA Shows 21.1-Month Survival in Small Cell Lung Cancer

Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, and raised full-year guidance to $38.9B-$39.7B. IMDELLTRA showed promising results in small cell lung cancer. Key products like Repatha and EVENITY saw significant growth. The company plans $2.6B in capital expenditures for 2026.

Original reporting
finance.biggo.com
Published Nov 3, 2026, 11:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
[Amgen Q3 2026 Earnings Call] Amgen Raises Full-Year Guidance as Revenue Hits $10.4B and IMDELLTRA Shows 21.1-Month Survival in Small Cell Lung Cancer — source image
Source · finance.biggo.com
Decision brief

The 30-second read

$AMGNBullishHigh
01

Why it matters

The combined financial and clinical updates provide a catalyst for short‑term price movement.

02

Market read

First‑report earnings and trial data create a high‑impact trading opportunity.

03

What to watch

Potential increased SG&A and capex could offset margin expansion.

Relevance 8/10Novelty 8/10Timing: immediate post‑earnings reaction

Background

Amgen's Q3 2026 earnings call disclosed revenue growth, guidance lift, and a key oncology trial result.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen raised its 2026 revenue and EPS guidance and reported positive Phase III results for IMDELLTRA in small cell lung cancer.

Expected impact

upward pressure as market prices in higher revenue outlook and potential FDA approval.

Evidence & confidence

Both revenue guidance and a pivotal oncology trial were disclosed for the first time, providing fresh, material information.

Market effects

Sector

Biotech sector may see broader optimism for oncology pipelines.

Regional

U.S. biotech stocks could rally on the earnings day.

Global

Positive data may influence global investors tracking US pharma earnings.

Counterpoint

What could challenge this read

If trial data fails to translate into regulatory approval, the guidance raise could be premature.

Key entities

  • company
    Amgen

    US‑listed biopharma reporting earnings and trial data.

Read at source← All news

StoryAmgen posts Q3 2026 earnings, lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

NOV 4
$AMGNMedAI 8/10

What Amgen (AMGN) Said on Its Q3 Earnings Call

Amgen reported Q3 sales growth in rare diseases and oncology, with BLINCYTO up 27% and TEPEZZA down 6%. Positive phase III results were announced for small cell lung cancer, eosinophilic esophagitis, and Sjögren's disease. MariTide obesity drug trials are advancing. Amgen raised 2026 revenue guidance to $38.9B-$39.7B and EPS to $22.90-$23.70, with a 6% dividend increase.

finance.yahoo.com7 min
NOV 3
$AMGNHighAI 9/10

AMGN Q3 FY2026 earnings call

Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, with 17 products growing double-digit. Non-GAAP operating margin was 47%, and free cash flow reached $3.7B. The company raised full-year 2026 guidance, expecting revenue of $38.9B-$39.7B and EPS of $22.90-$23.70. Key growth drivers include Repatha, EVENITY, TEZSPIRE, and UPLIZNA, with notable increases in rare disease and oncology portfolios.

finance.biggo.com2 min